Bourgi K, Rebeiro PF, Turner M, et al. - Treatment-naive persons living with human immunodeficiency virus (PLWH) starting integrase strand transfer inhibitor (INSTI)-based regimens vs other antiretroviral therapy (ART) regimens were examined for their relative weight gain. They assessed 1,152 adult, treatment-naive PLWH in the Vanderbilt Comprehensive Care Clinic cohort who were initiating INSTI-, protease inhibitor–, and nonnucleoside reverse transcriptase inhibitor (NNRTI)–based ART between January 2007 and June 2016. Among participants, INSTI-based regimens were provided to 351 (135 dolutegravir, 153 elvitegravir, and 63 raltegravir), 86% were male, and 49% were white. Observations revealed significantly more weight gain by 18 months among treatment-naive PLWH starting dolutegravir-based regimens vs those starting NNRTI-based and elvitegravir-based regimens.